08:00 , Nov 24, 2014 |  BC Week In Review  |  Clinical News

2MD: Phase IIb data

A double-blind, U.S. Phase IIb trial in 62 CKD patients receiving hemodialysis showed that thrice-weekly 220-770 ng oral DP001 for 12 weeks led to a 46% reduction in PTH levels vs. a 31% increase for...
07:00 , Oct 9, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Pancreatic cancer Vitamin D receptor (VDR) In vitro and mouse studies suggest vitamin D analogs could help treat pancreatic cancer. VDR levels were higher in...
07:00 , Mar 19, 2007 |  BC Week In Review  |  Clinical News

DP001: Phase II started

Deltanoid started a U.S. Phase II trial in postmenopausal women. Deltanoid Pharmaceuticals Inc. , Madison, Wis.   Product: DP001 , 2MD   Business: Autoimmune   Molecular target: NA   Description: Vitamin D analog   Indication:...
08:00 , Jan 20, 2003 |  BC Week In Review  |  Company News

Deltanoid, Pfizer deal

Deltanoid granted PFE an option to acquire development and marketing rights to its 2MD , an analog of vitamin D, to treat osteoporosis. PFE also would receive rights to certain other Deltanoid vitamin D analogs....
08:00 , Jan 20, 2003 |  BioCentury  |  Product Development

Deltanoid: Curiously strong

Deltanoid: Curiously strong Osteoporosis represents a large market with room for improvement. All but one of the marketed drugs for the disease slow or stop bone loss, but do not promote new bone formation. Thus,...
07:00 , Oct 7, 2002 |  BC Week In Review  |  Company News

Deltanoid Inc. other research news

Researchers published in the Proceedings of the National Academy of Sciences that 2MD at concentrations as low as 10 -12 M caused primary cultures of osteoblasts to produce bone. 2MD caused a 9% increase in...